Trulieve Cannabis Corp. quarterly report, Q1 FY2026

Trulieve Cannabis Corp. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2026. Trulieve Cannabis Corp. is a vertically integrated multi-state cannabis operator with 236 dispensaries and 15 cultivation/processing facilities across nine U.S. states. The company operates under a regional hub structure (Southeast, Northeast, Southwest) and is the largest cannabis retailer in the United States. A significant regulatory development occurred on April 23, 2026, when the U.S. Department of Justice finalized the rescheduling of medical marijuana from Schedule I to Schedule III, impacting federal tax and regulatory restrictions for medical operations.

Key Financial Metrics

Metric Q1 2026 Q1 2025
Revenue $286.8 million $297.8 million
Gross Profit $170.1 million $183.2 million
Gross Margin 59.3% 61.5%
Net Income (Loss) $2.3 million ($33.8 million)
Adjusted EBITDA $100.4 million $109.2 million
Operating Cash Flow $55.7 million $51.1 million
Cash and Equivalents $352.9 million $329.4 million
Total Debt (Notes Payable + Private Placement) $285.7 million $227.6 million

Material Changes vs. Prior Period

  • Revenue Decline: Revenue decreased 4% year-over-year to $286.8 million. This was driven by a $16.8 million drop in retail revenue due to price compression, partially offset by a $5.8 million increase in wholesale revenue.
  • Profitability Turnaround: The company reported a net income of $2.3 million, a significant improvement from a net loss of $33.8 million in Q1 2025. This shift was primarily due to a $30.6 million reduction in the provision for income taxes, as the company did not apply IRC Section 280E for the 2026 taxable year.
  • Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 12% to $104.9 million, largely due to a reduction in campaign and political contributions ($9.5 million vs. $23.0 million in the prior year).
  • Debt Increase: Total debt obligations increased due to the issuance of $60 million in new private placement notes (Tranche Two) in Q1 2026, bringing total private placement notes to $200 million.

Outlook, Risks, and Contingencies

  • Regulatory Outlook: Following the DOJ rescheduling of medical cannabis to Schedule III, Trulieve has applied for DEA licenses in Florida, Georgia, Pennsylvania, and West Virginia. Adult-use operations remain illegal under federal law until rescheduling is finalized.
  • Tax Contingencies: The company maintains a significant uncertain tax position liability of $696.4 million, primarily related to IRC Section 280E challenges. The IRS proposed penalties of approximately $38.1 million in September 2025, which the company intends to contest vigorously.
  • Liquidity: Management believes existing cash balances of $352.9 million are sufficient to meet requirements for the next 12 months. Future capital needs may be met through operations, debt, or equity financings.
  • Operational Risks: Risks include federal illegality of adult-use cannabis, potential civil asset forfeiture, RICO liability, and intense market competition.

Investor Verification Checklist

  • Tax Position Viability: Verify the status of the IRS audit and the likelihood of the company successfully defending its position against IRC Section 280E and the proposed $38.1 million penalty.
  • DEA Licensing: Monitor the approval status of DEA licenses for medical-only states following the Schedule III rescheduling.
  • Debt Covenants: Confirm continued compliance with financial covenants on the $200 million private placement notes and other long-term borrowings.
  • Price Compression: Assess the sustainability of retail revenue given the noted price compression trends in core markets.
  • Discontinued Operations: Review the ongoing impact of discontinued operations (Massachusetts and Nevada exits) on cash flow and asset reclassifications.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.